Policy & Regulation
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
24 December 2025 - Precision oncology company Repare Therapeutics Inc (Nasdaq: RPTX) announced on Wednesday that it has entered into a definitive asset purchase agreement with Gilead Sciences Inc for ...
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
24 December 2025 - R&D driven, AI-powered biopharma company Sanofi (Euronext Paris: SAN) (Nasdaq: SNY) announced on Wednesday that it has agreed to acquire Dynavax Technologies Corporation (Nasdaq...
Italfarmaco and JCR PHarmaceuticals strike Japan deal for givinostat and expand rare disease collaboration
24 December 2025 - Pharmaceutical companies Italfarmaco S.p.A. and JCR Pharmaceuticals Co, Ltd (TSE 4552) on Wednesday announced an exclusive licensing agreement granting JCR Pharmaceuticals rights to...
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
23 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Tuesday announced approval from J...
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
23 December 2025 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) announced on Monday that it has completed the safety analysis from its proof-of-concept Phase 2, ...